Sökning: WFRF:(Koopman Miriam) > Comparing Circulati...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03648naa a2200337 4500 | |
001 | oai:DiVA.org:uu-422997 | |
003 | SwePub | |
008 | 201019s2020 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4229972 URI |
024 | 7 | a https://doi.org/10.1158/1078-0432.CCR-19-25702 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Netterberg, Idau Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)idane961 |
245 | 1 0 | a Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival :b A Quantitative Modeling Framework |
264 | 1 | b AMER ASSOC CANCER RESEARCH,c 2020 |
338 | a print2 rdacarrier | |
520 | a Purpose: Quantitative relationships between treatment-induced changes in tumor size and circulating tumor cell (CTC) counts, and their links to overall survival (OS), are lacking. We present a population modeling framework identifying and quantifying such relationships, based on longitudinal data collected in patients with metastatic colorectal cancer (mCRC) to evaluate the value of tumor size and CTC counts as predictors of OS. Experimental Design: A pharmacometric approach (i.e., population pharmacodynamic modeling) was used to characterize the changes in tumor size and CTC count and evaluate them as predictors of OS in 451 patients with mCRC treated with chemotherapy and targeted therapy in a prospectively randomized phase III study (CAIRO2). Results: A tumor size model of tumor quiescence and drug resistance was used to characterize the tumor size time-course, and was, in addition to the total normalized dose (i.e., of all administered drugs) in a given cycle, related to the CTC counts through a negative binomial model (CTC model). Tumor size changes did not contribute additional predictive value when themean CTC count was a predictor of OS. Treatment reduced the typical mean count from 1.43 to 0.477 (HR = 3.94). The modeling framework was applied to explore whether dose modifications (increased and reduced) would result in a CTC count below 1/7.5 mL after 1 to 2 weeks of treatment. Conclusions: Time-varying CTC counts can be useful for early predicting OS in patients with mCRC, and may therefore have potential for model-based treatment individualization. Although tumor size was connected to CTC, its link to OS was weaker. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Karlsson, Matsu Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)matskarl |
700 | 1 | a Terstappen, Leon W. M. M.u Univ Twente, Fac Sci & Technol, Dept Med Cell BioPhys, Enschede, Netherlands.4 aut |
700 | 1 | a Koopman, Miriamu Univ Utrecht, Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands.4 aut |
700 | 1 | a Punt, Cornelis J. A.u Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Med Oncol, Amsterdam, Netherlands.4 aut |
700 | 1 | a Friberg, Lenau Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)lenasimo |
710 | 2 | a Uppsala universitetb Institutionen för farmaceutisk biovetenskap4 org |
773 | 0 | t Clinical Cancer Researchd : AMER ASSOC CANCER RESEARCHg 26:18, s. 4892-4900q 26:18<4892-4900x 1078-0432x 1557-3265 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-422997 |
856 | 4 8 | u https://doi.org/10.1158/1078-0432.CCR-19-2570 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.